Raúl González-Fregoso

Raúl González-Fregoso

San Luca Centro Vascular, Mexico

Title: Angiotensin II receptor blockers as a risk factor for skin ulcers


Objective: The aim of the study was to determine the risk factors associated with skin ulcers that were not of vascular, paraneoplastic, rheumatologic, or pressure origin. Methods: This was an observational, case- and control-designed, and retrospective trial. The group of cases was patients who presented skin ulcers that were not of vascular, paraneoplastic, or pressure origin. The control group was formed by ill subjects with no skin ulcers paired in age, sex, and chronic diseases. The cases were defined with the presence of an ulcer, at the 1st time consultation; treatment with medication, symptoms, progression time, and substance abuse were entered in a database. The statistical analysis of the results was performed using the EpiInfo software, version Results: Between July 2005 and December 2020, 69 patients suffering from skin ulcers without apparent etiology were enrolled. Following the statistical analysis of all variables, a significant difference in favor of the cases with antihypertensive treatment with angiotensin II receptor blockers (ARBs) was obtained, with p ? 0.02 and odds ratio 2.24 with confidence interval 95 % (1.1–4.5). Conclusion: ARB medications are a risk factor for the presence of skin ulcers. Key words: Skin ulcers. Angiotensin II receptor blockers. Nonvascular ulcers.


I am Dr. Raul Gonzalez-Fregoso and I am 52 years old. I have 22 years of experience in vascular surgery. Pioneer in vascular therapy in the state where I work, I published a book chapter and a worked about thromboprophylaxis in venous ablation. I presented one of the first works about venous arterialization at a diabetic foot conference in Milan in 2013. I worked as a professor at Queretaro State Medical University for 22 years. Currently, I am a member of the editorial board of the Revista Mexicana de Angiologia. My areas of research interest are venous thrombosis, varicose veins, diabetic foot, and wound care.